^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | telisotuzumab adizutecan (ABBV-400) (Topoisomerase I inhibitor, c-MET-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
163P - Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors
Published date:
10/16/2023
Excerpt:
The objective response rate was 25% (14/57; all confirmed partial responses [cPR]) in all pts and 22% in pts with CRC (6/27; all cPR)….The table shows the correlation between response and select biomarkers (at baseline) in the 45 pts (22 CRC) who had both ctDNA and radiographic response data. A molecular response was observed in 48% (14/29) of all evaluated pts and 47% (8/17) of pts with CRC; median change from baseline tumor size was -22.5% and -20.3%, respectively....ABBV-400 showed promising preliminary efficacy, with molecular and radiographic responses in pts with advanced solid tumors with heterogeneous genomic profiles, including in pts with high TMB and KRAS mutations.
Trial ID:
